Intermuscular vein thrombosis
Conditions
Interventions
6-weeks anticoagulant group:After diagnosis of MCVT, oral rivaroxaban 10 mg/time, QD until discharge
after discharge, oral rivaroxaban tablets 10 mg/time, QD, anticoagulant treatment until 6 weeks
3-months anticoagulant group:After diagnosis of MCVT, oral rivaroxaban 10 mg/time, QD until discharge
after discharge, oral rivaroxaban tablets 10 mg/time, QD, anticoagulant treatment until 3 months
Sponsors
The Second Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients who received major orthopaedic surgery in our hospital from March 2023 to March 2025 were selected. 1. Body weight 50-100 kg; 2. No abnormal coagulation system and no history of thrombosis; 3. Patients who adopt standard major orthopedic surgery procedures and rehabilitation procedures; 4. Patients with fresh isolated distal calf intermuscular vein thrombosis confirmed by postoperative color ultrasound of lower extremity deep vein; 5. The routine anticoagulant regimen for VTE prevention was adopted in the perioperative period: anticoagulant drugs were stopped 12 h before surgery, and enoxaparin sodium 4,000 Axaiu/time was given 12-24 h after surgery, QD; 6. Voluntary participation and cooperation in the completion of this study.
Exclusion criteria
Exclusion criteria: 1. Preoperative ultrasonography showed the presence of thrombus in the lower extremities; 2. Cancer patients; 3. Patients who are at risk of severe bleeding and cannot receive ordinary anticoagulant therapy (active bleeding, recent hemorrhagic stroke or upper gastrointestinal bleeding, etc.); 4. Restricted activity affected the outcome of thrombus; 5. Combined with thrombosis in other parts (central deep vein thrombosis of lower extremity or combined with pulmonary embolism); 6. A wide range of involvement (more than 5 cm in length, multiple veins involved or a maximum diameter of more than 7 mm); 7. Antiphospholipid syndrome or symptomatic hereditary propensity to thrombosis; 8. pregnancy; 9. Use birth control pills or hormone replacement therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of intermuscular vein thrombosis; | — |
Countries
China
Contacts
Public ContactZhu Zhu
The Second Affiliated Hospital of Soochow University
Outcome results
None listed